Primary results from the GALILEO trial, presented at the American Heart Association’s annual meeting this November, suggest patients undergoing TAVR with no ongoing indication for oral anticoagulation benefit more from an antiplatelet-based treatment approach than a rivaroxaban-based approach.

Joint research from the American Heart Association and American Medical Association suggests that just half of practicing physicians and healthcare professionals have received blood pressure measurement training since they left school.

Use of the Impella heart pump during PCI rose rapidly between the 2000s and 2010s, according to a Circulation analysis—but so did its variability across hospitals and associated adverse outcomes.

A senior at a Utah high school received a scholarship this month based on her idea for an automated CPR assistance device.

The FDA has granted Breakthrough Device status to BioVentrix, Inc.’s Revivent TC Transcatheter Ventricular Enhancement System, a proactive approach to treating MI-induced heart failure.

A new structural heart disease initiative from the American Heart Association and Edwards Lifesciences will aim to raise patient awareness of valve diseases while enriching patient education and engagement.

Nearly one-third of insured adults with diagnosed hypertension were nonadherent to their antihypertensive medications in 2015, according to a report published Nov. 4 in Hypertension.

A novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure, according to research published in the journal Thorax.